Br-RT characteristics
| Characteristic . | n (%) or median (IQR) . |
|---|---|
| By patient (N = 172) | |
| Interval from leukapheresis to Br-RT start, d | 4 (–9 to 11)∗ |
| Interval from Br-RT end to CAR-T infusion, d | 15 (10-24) |
| Comprehensive Br-RT (to all active lesions) | 67 (39) |
| Nodal/extranodal | |
| Nodal | 61 (35) |
| Extranodal | 67 (39) |
| Mixed | 26 (15) |
| Unknown | 18 (10) |
| Maximum diameter of largest treated lesion (cm)† | 6 (3.5-10.5) |
| Concurrent systemic therapy | |
| Yes | 39 (23) |
| No | 116 (67) |
| Unknown | 17 (10) |
| RT technique | |
| 3D-CRT | 77 (45) |
| IMRT/VMAT | 69 (40) |
| 3D-CRT/IMRT mix | 5 (3) |
| Electron therapy | 3 (2) |
| Stereotactic radiosurgery | 2 (1) |
| Proton therapy | 1 (<1) |
| IMRT/Proton therapy mix | 1 (<1) |
| Unknown | 14 (8) |
| No. of sites treated with Br-RT | |
| 1 | 139 (81) |
| 2 | 20 (12) |
| 3 | 8 (5) |
| 4 | 5 (3) |
| ByBr-RTsite (N = 223) | |
| Sites treated | |
| Abdomen/pelvis | 78 (35) |
| Head/neck | 50 (22) |
| Thorax | 30 (13) |
| Extremity/soft tissue | 27 (12) |
| Spine/paraspinal | 14 (6) |
| CNS‡ | 13 (6) |
| Focal brain | 7 |
| Whole brain | 2 |
| Optic nerve | 3 |
| Leptomeningeal disease | 1 |
| Axilla | 11 (5) |
| Total dose, Gy§ | 25 (20-30.6) |
| No. of fractions§ | 10 (5-15) |
| Dose per fraction, Gy§ | 2.8 (2-4) |
| EQD2, Gy (alpha/beta = 10)§ | 29.3 (21-33) |
| Most common regimens§ | |
| 30 Gy/10 fractions | 35 (16) |
| 20 Gy/5 fractions | 29 (13) |
| 20 Gy/10 fractions | 9 (4) |
| 37.5 Gy/15 fractions | 9 (4) |
| Characteristic . | n (%) or median (IQR) . |
|---|---|
| By patient (N = 172) | |
| Interval from leukapheresis to Br-RT start, d | 4 (–9 to 11)∗ |
| Interval from Br-RT end to CAR-T infusion, d | 15 (10-24) |
| Comprehensive Br-RT (to all active lesions) | 67 (39) |
| Nodal/extranodal | |
| Nodal | 61 (35) |
| Extranodal | 67 (39) |
| Mixed | 26 (15) |
| Unknown | 18 (10) |
| Maximum diameter of largest treated lesion (cm)† | 6 (3.5-10.5) |
| Concurrent systemic therapy | |
| Yes | 39 (23) |
| No | 116 (67) |
| Unknown | 17 (10) |
| RT technique | |
| 3D-CRT | 77 (45) |
| IMRT/VMAT | 69 (40) |
| 3D-CRT/IMRT mix | 5 (3) |
| Electron therapy | 3 (2) |
| Stereotactic radiosurgery | 2 (1) |
| Proton therapy | 1 (<1) |
| IMRT/Proton therapy mix | 1 (<1) |
| Unknown | 14 (8) |
| No. of sites treated with Br-RT | |
| 1 | 139 (81) |
| 2 | 20 (12) |
| 3 | 8 (5) |
| 4 | 5 (3) |
| ByBr-RTsite (N = 223) | |
| Sites treated | |
| Abdomen/pelvis | 78 (35) |
| Head/neck | 50 (22) |
| Thorax | 30 (13) |
| Extremity/soft tissue | 27 (12) |
| Spine/paraspinal | 14 (6) |
| CNS‡ | 13 (6) |
| Focal brain | 7 |
| Whole brain | 2 |
| Optic nerve | 3 |
| Leptomeningeal disease | 1 |
| Axilla | 11 (5) |
| Total dose, Gy§ | 25 (20-30.6) |
| No. of fractions§ | 10 (5-15) |
| Dose per fraction, Gy§ | 2.8 (2-4) |
| EQD2, Gy (alpha/beta = 10)§ | 29.3 (21-33) |
| Most common regimens§ | |
| 30 Gy/10 fractions | 35 (16) |
| 20 Gy/5 fractions | 29 (13) |
| 20 Gy/10 fractions | 9 (4) |
| 37.5 Gy/15 fractions | 9 (4) |
3D-CRT, 3-dimensional conformal radiotherapy; IMRT, intensity modulated radiotherapy; VMAT, volumetric modulated arc therapy.
Negative number (−9) indicates radiotherapy was started before leukapheresis.
Unavailable for 38 patients.
Thirteen sites treated among 8 patients.
Excluding 1 patient with missing dose/fractionation details.